Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Allert H. Vos"'
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial
Autor:
Mark Opdam, Annelot G.J. van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M. Horlings, Erik van Werkhoven, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J. Rutgers, Renee X. de Menezes, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Sabine C. Linn, Marcel Soesan, Rianne M. Oosterkamp, Frank Jeurissen, Nir Weijl, Karin J. Beelen, Aart van Bochove, Gerty de Klerk, Suzan Vrijaldenhoven, Annette van der Velden, Hiltje de Graaf, Marielle Smeets, Jetske Meerum Terwogt, Jolanda Schrama, Philomeen Kuijer, Hanneke Wilmink, Ronald Hoekstra, Judith Kroep, Hans F.M. Pruijt, Leander van Gerven, Allert H. Vos, Frans Erdkamp, Willemien G. van Leeuwen-Breuk, Alexander de Graeff
Publikováno v:
iScience, Vol 27, Iss 8, Pp 110425- (2024)
Summary: The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can
Externí odkaz:
https://doaj.org/article/3dae747c44804a5fafa1281b33a3c21c
Autor:
Pieter Sonneveld, Floortje Mols, Lonneke V. van de Poll-Franse, Silvia G. R. Verelst, Allert H Vos, Simone Oerlemans, Annemarie Koster
Publikováno v:
European Journal of Haematology, 89(4), 311-319. Wiley-Blackwell
Background: This prospective population-based study describes health-related quality of life (HRQOL) and disease-specific complaints of patients with multiple myeloma (MM) up to 10 yr post-diagnosis. Methods: The Eindhoven Cancer Registry was used to